The effect of salmeterol and salbutamol on mediator release and skin responses in immediate and late phase allergic cutaneous reactions.
BACKGROUND
Salmeterol is a long-acting beta2-agonist which in animal studies has been shown to possess anti-inflammatory effects on early (EAR) and late (LPR) phase allergic responses.


OBJECTIVE
To evaluate the anti-inflammatory effects of intradermally injected salmeterol and salbutamol on clinical and biochemical EAR and LPR in human skin.


METHODS
Measurement of wheal and flare reactions to allergen, codeine, and histamine, and LPR (induration) to allergen. Assessment of histamine and prostaglandin D2 (PGD2) release by microdialysis technique in EAR, and measurement of mediators in LPR by suction blister technique.


RESULTS
Both beta2-agonists inhibited allergen-induced histamine release and wheal and flare reactions with maximum inhibition of 40-50% at 10(-6) M, a concentration which reduced PGD2 synthesis by approximately 55%. Histamine release by codeine and skin reactions to codeine and histamine were not or only marginally reduced. Salmeterol and salbutamol (10(-6) M) inhibited clinical LPR at 6 h by 71% and 48%, Except for the clinical LPR, no statistical differences were found between the two drugs on any parameters. None of the drugs inhibited levels of histamine, tryptase, myeloperoxidase, or eosinophil cationic protein in LPR.


CONCLUSIONS
Salmeterol and salbutamol inhibited allergen-induced skin responses, and reduced mediator release in EAR but not LPR. In general, the anti-inflammatory effects of salmeterol did not differ from those induced by salbutamol.
Petersen
L J
LJ
Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
Skov
P S
PS
D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006632:Histamine / Q000032:analysis; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D008297:Male; D006109:Poaceae; D011058:Pollen; D015230:Prostaglandin D2 / Q000032:analysis; D012044:Regression Analysis; D000068299:Salmeterol Xinafoate; D012882:Skin Tests; D013997:Time Factors
D000318:Adrenergic beta-Agonists; D000485:Allergens; D018836:Inflammation Mediators; D000068299:Salmeterol Xinafoate; D006632:Histamine; D000420:Albuterol; D015230:Prostaglandin D2